Progression of Lysosomal Acid Lipase Deficiency (LAL-D)

Liver Progression In LAL-D Is Rapid and Can Lead to Fibrosis, CIRRHOSIS, and Liver Transplant Within a Few Years³

KAPLAN-MEIER ESTIMATE: TIME AND RISK FROM FIRST LAL-D CLINICAL MANIFESTATION TO FIRST DOCUMENTATION OF HEPATIC FIBROSIS, CIRRHOSIS, OR LIVER TRANSPLANTATION IN 32 PEDIATRIC AND ADULT PATIENTS WITH LAL-D^3,a

Figure adapted from Burton BK, et al. Curr Med Res Opin. 2017;33(7):1211-1214. © 2017 Taylor Francis, reprinted by permission of the publisher Taylor & Francis Ltd.
^aPost hoc analysis of an observational study in 31 patients with LAL-D with liver biopsy data and 1 patient with no biopsy who received liver transplantation.
^b“At risk” numbers aligned with the x-axis indicate the number of patients who have not yet had a documented occurrence of hepatic fibrosis, cirrhosis, or liver transplantation.

Nearly 50% of patients with LAL-D progress to fibrosis, cirrhosis, or liver transplant within 3 years of first clinical manifestation³

Persistently elevated LDL-C in LAL-D can increase the risk for severe cardiovascular events¹

LDL-C levels in LAL-D can be similar to the levels in other hereditary dyslipidemias, highlighting the need to rule out LAL-D^4-6

Image adapted from Bernstein DL, et al. J Hepatol. 2013;58(6):1230-1243, Pericleous M, et al. Lancet Gastroenterol Hepatol. 2017;2:670-679, and Burton BK, et al. Curr Med Res Opin. 2017;33(7):1211-1214.

NOTE: These studies represent individual publications using different patient populations. Data are not directly comparable.

Abbreviations: FCH, familial combined hyperlipidemia; HeFH, heterozygous familial hypercholesterolemia; LAL-D, lysosomal acid lipase deficiency; LDL-C, low-density lipoprotein cholesterol.

References: 1. Bernstein DL, et al. J Hepatol. 2013;58(6):1230-1243. 2. Pericleous M, et al. Lancet Gastroenterol Hepatol. 2017;2:670-679. 3. Burton BK, et al. Curr Med Res Opin. 2017;33(7):1211-1214. 4. Kusters DM, et al. JAMA. 2014;312(10):1055-1057. 5. Veerkamp MJ, et al. Arterioscler Thromb Vasc Biol. 2002;22(2):274-282. 6. Burton BK, et al. J Pediatr Gastroenterol Nutr. 2015;61(6):619-625. 7. Lukacs Z, et al. Clinica Chimica Acta. 2017;471:201-205. 8. Reiner Ž, et al. Atherosclerosis. 2014;235(1):21-30.

Chronic hyperlipidemia, accelerated atherosclerosis, and liver failure have led to

STROKE AND MYOCARDIAL INFARCTION

in patients with LAL-D

Liver Progression In LAL-D Is Rapid and Can Lead to Fibrosis, CIRRHOSIS, and Liver Transplant Within a Few Years³

KAPLAN-MEIER ESTIMATE: TIME AND RISK FROM FIRST LAL-D CLINICAL MANIFESTATION TO FIRST DOCUMENTATION OF HEPATIC FIBROSIS, CIRRHOSIS, OR LIVER TRANSPLANTATION IN 32 PEDIATRIC AND ADULT PATIENTS WITH LAL-D^3,a

Nearly 50% of patients with LAL-D progress to fibrosis, cirrhosis, or liver transplant within 3 years of first clinical manifestation³

Persistently elevated LDL-C in LAL-D can increase the risk for severe cardiovascular events¹

LDL-C levels in LAL-D can be similar to the levels in other hereditary dyslipidemias, highlighting the need to rule out LAL-D^4-6

Test for LAL-D with a simple blood test that includes a blood draw^7,8

REGISTER TODAY
and receive all the latest LAL-D information.

Chronic hyperlipidemia, accelerated atherosclerosis, and liver failure have led to

STROKE AND MYOCARDIAL INFARCTION

in patients with LAL-D

Liver Progression In LAL-D Is Rapid and Can Lead to Fibrosis, CIRRHOSIS, and Liver Transplant Within a Few Years3

KAPLAN-MEIER ESTIMATE: TIME AND RISK FROM FIRST LAL-D CLINICAL MANIFESTATION TO FIRST DOCUMENTATION OF HEPATIC FIBROSIS, CIRRHOSIS, OR LIVER TRANSPLANTATION IN 32 PEDIATRIC AND ADULT PATIENTS WITH LAL-D3,a

Nearly 50% of patients with LAL-D progress to fibrosis, cirrhosis, or liver transplant within 3 years of first clinical manifestation3

Persistently elevated LDL-C in LAL-D can increase the risk for severe cardiovascular events1

LDL-C levels in LAL-D can be similar to the levels in other hereditary dyslipidemias, highlighting the need to rule out LAL-D4-6

Test for LAL-D with a simple blood test that includes a blood draw7,8

REGISTER TODAY and receive all the latest LAL-D information.

Liver Progression In LAL-D Is Rapid and Can Lead to Fibrosis, CIRRHOSIS, and Liver Transplant Within a Few Years³

KAPLAN-MEIER ESTIMATE: TIME AND RISK FROM FIRST LAL-D CLINICAL MANIFESTATION TO FIRST DOCUMENTATION OF HEPATIC FIBROSIS, CIRRHOSIS, OR LIVER TRANSPLANTATION IN 32 PEDIATRIC AND ADULT PATIENTS WITH LAL-D^3,a

Nearly 50% of patients with LAL-D progress to fibrosis, cirrhosis, or liver transplant within 3 years of first clinical manifestation³

Persistently elevated LDL-C in LAL-D can increase the risk for severe cardiovascular events¹

LDL-C levels in LAL-D can be similar to the levels in other hereditary dyslipidemias, highlighting the need to rule out LAL-D^4-6

Test for LAL-D with a simple blood test that includes a blood draw^7,8

REGISTER TODAY
and receive all the latest LAL-D information.